Is a Correction Looming Ahead for BioXcel Therapeutics Inc. (BTAI) – News Heater
Home  »  Companies   »  Is a Correction Looming Ahead for BioXcel Therapeu...

Is a Correction Looming Ahead for BioXcel Therapeutics Inc. (BTAI)

BioXcel Therapeutics Inc. (NASDAQ:BTAI) went up by 11.27% from its latest closing price compared to the recent 1-year high of $39.00. The company’s stock price has collected -21.52% of loss in the last five trading sessions.

Is It Worth Investing in BioXcel Therapeutics Inc. (NASDAQ :BTAI) Right Now?

Plus, the 36-month beta value for BTAI is at 1.29. Opinions of the stock are interesting as 8 analysts out of 9 who provided ratings for BioXcel Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 1 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

The average price from analysts is $54.33, which is $69.06 above the current price. BTAI currently public float of 18.95M and currently shorts hold a 20.73% ratio of that float. Today, the average trading volume of BTAI was 785.14K shares.

BTAI’s Market Performance

BTAI stocks went down by -21.52% for the week, with a monthly drop of -31.68% and a quarterly performance of -40.45%, while its annual performance rate touched -64.61%. The volatility ratio for the week stands at 15.93% while the volatility levels for the past 30 days are set at 10.20% for BioXcel Therapeutics Inc.. The simple moving average for the period of the last 20 days is -20.96% for BTAI stocks with a simple moving average of -52.57% for the last 200 days.

Analysts’ Opinion of BTAI

Many brokerage firms have already submitted their reports for BTAI stocks, with BofA Securities repeating the rating for BTAI by listing it as a “Buy.” The predicted price for BTAI in the upcoming period, according to BofA Securities is $80 based on the research report published on April 06th of the current year 2022.

Goldman, on the other hand, stated in their research note that they expect to see BTAI reach a price target of $24, previously predicting the price at $55. The rating they have provided for BTAI stocks is “Sell” according to the report published on November 15th, 2021.

Berenberg gave a rating of “Buy” to BTAI, setting the target price at $75 in the report published on April 09th of the previous year.

BTAI Trading at -34.88% from the 50-Day Moving Average

After a stumble in the market that brought BTAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.41% of loss for the given period.

Volatility was left at 10.20%, however, over the last 30 days, the volatility rate increased by 15.93%, as shares sank -33.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.21% lower at present.

During the last 5 trading sessions, BTAI fell by -21.52%, which changed the moving average for the period of 200-days by -59.76% in comparison to the 20-day moving average, which settled at $13.35. In addition, BioXcel Therapeutics Inc. saw -47.07% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BTAI starting from Nandabalan Krishnan, who sale 473,250 shares at the price of $30.83 back on Jun 25. After this action, Nandabalan Krishnan now owns 8,546,750 shares of BioXcel Therapeutics Inc., valued at $14,589,493 using the latest closing price.

Mehta Vimal, the CEO, President and Secretary of BioXcel Therapeutics Inc., sale 473,250 shares at $30.83 during a trade that took place back on Jun 25, which means that Mehta Vimal is holding 8,546,750 shares at $14,589,493 based on the most recent closing price.

Stock Fundamentals for BTAI

Equity return is now at value -46.40, with -43.50 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 14.21.

Leave a Comment

Your email address will not be published.

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam